On October 4, 2021 NKMax, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, reported that an abstract highlighting key data from a Phase I SNK01 study in Non-Small Cell Lung Cancer (NSCLC) has been accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) being held November 10 – 14, 2021, in Washington, D.C (Press release, NKMax America, OCT 4, 2021, View Source [SID1234590741]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation
Title: Phase I/IIa randomized trial evaluating safety and efficacy of SNK01 plus Pembrolizumab in patients with Stage IV Non-Small Cell Lung Cancer (NSCLC) who have failed first-line platinum-based therapy
Abstract: #1010
Poster Presentation Date and Time: November 10, 2021 from 6:00 pm – 7:00 pm EST
The poster presentation will disclose final data from the Phase I/IIa SNK01 (autologous ex-vivo activated & expanded cytotoxic NK Cells) + pembrolizumab clinical trial conducted in patients with NSCLC.
Abstracts will be available for viewing on the SITC (Free SITC Whitepaper) Annual Meeting website on November 9, 2021 at 8:00 am EST. www.sitcancer.org/2021